Davis Hugh M. 4
4 · Aclaris Therapeutics, Inc. · Filed Feb 4, 2025
Insider Transaction Report
Form 4
Davis Hugh M.
DirectorPresident and COO
Transactions
- Award
Restricted Stock Units
2025-02-03+74,700→ 74,700 total→ Common Stock (74,700 underlying) - Award
Employee Stock Option (Right to Buy)
2025-02-03+261,600→ 261,600 totalExercise: $2.40Exp: 2035-02-02→ Common Stock (261,600 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
- [F2]The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
- [F3]Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.